In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $139.75, along ...

Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...

In a report released yesterday, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...

TD Cowen analyst Joseph Thome maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $125.00.

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease ...